TaiGen Biotechnology files IND for influenza antiviral TG-1000
Category: #headline  By Mateen Dalal  Date: 2020-10-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

TaiGen Biotechnology files IND for influenza antiviral TG-1000

TaiGen Biotechnology Co., Ltd., a Taiwan-based company that focuses on the development and commercialization of treatments for infectious diseases, cancers and diabetic complications, has announced that its influenza antiviral drug TG-1000 has been filed for an Investigational New Drug (IND) application with the US FDA.

For the record, TG-1000 is a pan-influenza antiviral, which abstains viral replication and transmission using a cap-snatching mechanism. The drug is developed to target avian flu H7N9, influenza-A, influenza-B, and Tamiflu-resistant viruses.

As per reports, TG-1000 has successfully received its first US patent from the United States Patent and Trademark Office for prosecuted on Jan 14th, 2020. Following that, in July 2020, a Phase 1 trial was initiated by TaiGen in China which successfully completed the first 4 groups in the single ascending dose part.

Recently, a Phase 2 protocol was submitted to the institutional review board (IRB) of China-Japan Friendship Hospital in Beijing.

Commenting on the latest development, Kuo-Lung Huang, Chairman and Chief Executive Officer, TaiGen,  said that their firm is thrilled about the US IND filing for the novel TG-1000 which could come up as a single dose treatment for influenza. TG-1000 IND filing exhibits TaiGen's capacity and experience in research & development of NCEs. 

About TaiGen Biotechnology

TaiGen Biotechnology is a one of the leading biotechnology company in Taiwan. Apart from the novel TG-1000 influenza antiviral therapy, TaiGen has three other in-house discovered NCEs, namely TG-3000, a chemokine receptor antagonist for chemosensitization and stem cell transplantation, Taigexyn®, a new non-fluorinated quinolone present in both intravenous and oral formulations, and Furaprevir, a HCV protease inhibitor for chronic hepatitis infection treatment.

Reportedly, TG-3000 has completed Phase 2 clinical trials, Taigexyn® is being commercialized in the market in Taiwan and the mainland China, and Furaprevir is in its Phase 3 clinical development.

Source Credit: https://www.prnewswire.com/news-releases/taigen-filed-us-ind-for-its-influenza-antiviral-tg-1000-301145272.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Eon to use linguistics model to identify IPN and manage lung cancer
Eon to use linguistics model to identify IPN and manage lung cancer
By Mateen Dalal

Eon, a healthcare technology company, has announced the expansion of its data science models. The mo...

AE Industrial Acquires PCI; Adds New Government Tech Investment
AE Industrial Acquires PCI; Adds New Government Tech Investment
By Mateen Dalal

AE Industrial Partners (AEI), a private equity firm specializing in Defense, Aerospace & Governm...

Spectrum Brands buys Armitage to expand its pet solutions portfolio
Spectrum Brands buys Armitage to expand its pet solutions portfolio
By Mateen Dalal

U.S.-based Fortune 500 company Spectrum Brands Holdings Inc. has reportedly announced the acquisitio...